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 Abstract
We present a substantially improved design and functionality of a centrifugo-
magnetophoretic platform which integrates direct immunoseparation and cost-
efficient, bright-field detection of cancer cells in whole blood. All liquid handling takes
place in a disposable cartridge with geometry akin to a conventional compact disc
(CD). The instrumentation required to process such a “lab-on-a-disc” cartridge can be
as simple and cost-efficient as the rotor on a common optical disc drive. In a first step,
target cells in a blood sample are specifically bound to paramagnetic microbeads. The
sample is then placed into the disc cartridge and spun. In the second step, magnetically
tagged target cells are separated by a co-rotating, essentially lateral magnetic field from
the background population of abundant blood cells, and also from unbound magnetic
beads. A stream of target cells centrifugally sediments through a stagnant liquid phase
into a designated detection chamber. The continuous, multiforce immunoseparation
proceeds very gently, i.e. the mechanical and hydrodynamic stress to the target cells is
minimized to mitigate the risk of cell loss by collective entrapment in the background
cells or vigorous snapping against a wall. We successfully demonstrate the extraction of
MCF7 cancer cells at concentrations as low as 1 target cell per ll from a background of
whole blood, with capture efficiencies of up to 88%. Its short time-to-answer is a nota-
ble characteristic of this system, with 10% of target cells collected in the first minute
after their loading to the system and the remainder captured within the following 10
min. All the above-mentioned factors synergetically combine to leverage the develop-
ment of a prospective point-of-care device for CTC detection. VC 2014 International Society
for Advancement of Cytometry
 Key terms
rare cell separation; centrifugal microfluidics; lab-on-a-disc; CTC detection; stopped
flow
OVER the past two decades interest in the centrifugal microfluidic lab-on-a-disc
(LoaD) concept (1,2) has significantly increased, in particular for bioanalytical
assays. The platform has been applied to successfully integrate liquid handling and
detection for endpoints such as sample nucleic acid amplification, immunoassays
(3), and cell analysis (4,5). The use of the inherent centrifugal field to transport and
manipulate (liquid) analytes and reagents (rather than through complex actuation
schemes such as pumps) makes the LoaD platforms particularly attractive for point-
of-care (PoC) settings where both cost-efficiency and robustness are prerequisites.
Processing of the disposable disc-cartridge generally requires a speed-adjustable spin-
dle motor as, for instance, found in conventional DVD players; indeed, such
cartridges have previously been processed by the DVD-ROM drive of a laptop (6).
Additionally, the innate ability of centrifugal sedimentation makes LoaD platforms
particularly suited to blood processing and cell handling.
Biomedical Diagnostics Institute,
National Centre of Sensor Research,
School of Physical Sciences, Dublin City
University, Dublin, Ireland
Received 27 March 2014; Revised 5
September 2014; Accepted 17 October
2014
Grant sponsor: Science Foundation Ire-
land, Grant number: 10/CE/B1821
Grant sponsor: ERDF and Enterprise Ire-
land, Grant number: CF 2011 1317
Additional Supporting Information may be
found in the online version of this article.
*Correspondence to: Jens Ducree, Dublin
City University, School of Physical Scien-
ces, Glasnevin, Dublin 9, Ireland. E-mail:
jens.ducree@dcu.ie
Published online 29 October 2014 in
Wiley Online Library (wileyonlinelibrary.
com)
DOI: 10.1002/cyto.a.22588
VC 2014 International Society for
Advancement of Cytometry
Cytometry Part A  87A: 7480, 2015
Original Article
Very dynamically emerging trends of personalised medi-
cine and acute healthcare have underpinned the need for
advanced point-of-care (PoC) devices or companion diagnos-
tics which can be deployed at the bedside in hospitals, in doc-
tor’s offices, and even at home for patient self-testing.
Classically these tests have been carried out in central labora-
tories, involving long time-to-answer and high costs of instru-
mentation. Microfluidic platforms bear the promise to
enhance patient comfort through fewer visits to clinics and
more gentle blood sampling due to reduced volume require-
ments while alleviating the burden on health-care budgets. A
notable example is the large-scale HIV monitoring in
resource-poor settings of Sub-Saharan Africa, where a number
of microfluidic technologies for rapid, minimum-
infrastructure PoC testing and timely initiation of medical
intervention. Much of these microtechnologies are based on
cell analysis from whole blood samples (7).
In addition to mobile monitoring of disease, these devices
have also become a major driver of cell-based medical analysis
in clinics and hospitals. A primary objective for such applica-
tion is in the detection of extremely rare circulating tumour
cells (CTCs) in whole blood samples. The field has considerably
advanced in recent years (8,9), with a growing number of
research groups investigating a range of aspects, from biological
characteristics of cancer cells (10) such as the links between
CTCs and metastases (11), to instrumentation designed for
diagnostics based on counting the actual CTC numbers present
in the blood (12), associated prognosis (13), methods of enu-
merating and detecting CTCs (8,14,15) and research into devel-
oping diagnostic devices which are able to detect CTCs in
typical clinical settings (9). Tools for CTC detection are
expected to provide important, ideally patient-specific informa-
tion for cancer prognosis, diagnosis, assessment of minimal
residual disease, and assessment of anti-cancer drugs (16).
Much effort is directed towards the development of micro-
fluidic systems for detecting CTCs (17–21). The paramount
challenge is the extreme sparseness of such cells. While the CTC
concentration in a patient sample is known to vary greatly with
cancer type and stage (14), the scientific community has not
yet been able to define a gold standard experiment for the
unambiguous identification of a CTC; hence also a wide con-
sensus on their concentration range is notably lacking. Never-
theless, we here follow the assumption of a concentration in the
range of 1 cell per ml. However, note that some work refers to
concentrations as low as 1 cell per ml, a concentration which
would require an initial enrichment on our current system, for
instance implementing RBC lysis or buffy coat extraction. Due
to the extreme paucity of these cells, an efficient and reliable
diagnostic instrument must meet particular performance crite-
ria: (i) a capture platform must isolate the entire CTC popula-
tion present (low loss, high capture efficiency), (ii) discard
background non-target cells (high isolation purity/specificity),
(iii) perform this analysis sufficiently fast, and (iv) handle
rather large volumes of sample (high system throughput) (9).
CTCs have been distinguished based on size, deformability
and density (22–24). However, these physical parameters may
significantly vary throughout the CTC population and thus
also lead to significant overlap with normal cells. The majority
of platforms, including the first commercially available CTC
diagnostic system (Cellsearch, Veridex), therefore identifies
CTCs based primarily on their specific protein marker expres-
sion such as epithelial cell adhesion molecule (EpCAM) via
immunoaffinity binding (14) or immunomagnetic isolation
(25–30). In addition, negative markers, biophysical characteris-
tics (e.g. size and deformability) and morphological analysis of
CTC candidates are commonly employed.
Here we present work on a novel centrifugal microfluidic
system that can magnetically isolate, enumerate, and detect rare
cells on a low-complexity platform which is highly amenable to
PoC diagnostics. Our previous work demonstrated continuous
separation of magnetic beads of varying sizes from a large back-
ground of cell-mimicking beads (31) and HIV relevant cell sep-
aration of CD4-positive cells (32). We have now critically
advanced the earlier technology to isolate much lower, biologi-
cally relevant concentrations of CTC-mimicking, cultured
MCF7 breast cancer cells (from cell lines) spiked into a whole
blood sample. We use paramagnetic, antibody-coated microbe-
ads which target the MCF7 cells by binding to the EpCAM epi-
tope expressed on these cells with very high specificity. Our
continuous-mode, centrifugo-magnetophoretic system can
therefore separate the input sample into its three superordinate
constituents: (red and white) blood cells, magnetically tagged
target (cancer) cells and excess unbound magnetic beads.
A unique feature of this multiforce separation is the
removal of unbound paramagnetic beads from tagged magnetic
cells based upon the synergistic interplay of magnetic and cen-
trifugal fields with the size-dependent Stokes drag. While many
platforms (32,33) have used magnetic separation, they lack the
ability to remove unbound magnetic beads from isolated tagged
target cells. This is because such a purification, e.g. through
integrated size filtration, tends to be prone to clogging and
unspecific trapping, and may thus lead to the loss of scarce tar-
get cells which would be prohibitive for rare cell detection. Our
filter-less, flow-less sedimentation-driven system presented
here, by design, eliminates this critical flaw. Through the con-
tinuous sedimentation scheme, we also mitigate the risk of cell
damage due to vigorous snapping of beads against the vessel
wall and the risk of collective pull of entrapped target cells by
the abundant background population into the waste; these par-
asitic loss mechanisms are deemed prevalent in common
batch-mode magnetostatic separations.
Alongside presenting, for the first time, isolation of
EpCAM positive cancer cells in biologically relevant concen-
trations using continuous centrifugo-magnetophoresis, we
also demonstrate a proof-of-concept of a simple, bight-field
method to quantitate the number of isolated cells based on
their packing volume in the capture chamber. This technique
is similar to established packed-cell-volume (PCV) haematoc-
rit measurement (34) and other diagnostics platforms (7).
WORKING PRINCIPLE
In our stopped-flow, continuous sedimentation
centrifugo-magnetophoresis (i.e. particle sedimentation
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through a stationary liquid on a centrifugal platform with
magnetic separation), the three forces governing the path of
the particles through the system are the centrifugal force Fx,
the essentially lateral magnetic force Fm, and the hydrody-
namic Stokes drag Fs (Fig. 1) (31). Nonmagnetic background
blood cells will only experience the radial centrifugal force Fx
and the counteracting Stokes drag Fs to sediment on a straight
path toward the peripheral edge of the disc. Concurrently,
magnetic particles will additionally experience the lateral mag-
netic field Fm, and thus deflect from the main stream.
The separation between unbound magnetic beads and
the magnetically tagged cancer cells (Fig. 1c) is primarily gov-
erned by the differences of (the densities of) their magnetic
momenta (31); the bulk magnetized beads possess a notably
larger mean magnetic momentum than the much larger cell/
bead hybrids which only exhibit a magnetization on the sur-
face of their biological core. The resulting differential in lateral
magnetic deflection is enhanced by the steep increase of field
gradient toward the co-rotating magnet, which thus amplifies
the spatial separation compared with a (hypothetical) uniform
field.
The two other factors, the centrifugal field and the vis-
cous Stokes drag, are significantly smaller in magnitude and
do not directly alter the deflection of the particle, i.e. the
principal discriminator of our spatial separation technique.
Instead, the interplay of these two counteracting forces mainly
impacts the (radial) speed of sedimentation, which is only
indirectly resolved by our technique through the residence
time of the particles within the impact zone of magnetic
deflection. However, the density differences between our types
of bioparticles are significantly less pronounced than the dif-
ferences in their magnetization, so the centrifugal field only
constitutes a secondary effect in our separation mechanism.
Our stopped-flow centrifugo-magnetophoresis therefore
drives a central stream of copious background cells into the
radially aligned, main waste chamber (labeled “waste” in Fig.
1c). The most strongly magnetized, free beads are vigorously
removed into a laterally aligned “gutter” chamber (labeled
“gutter” in Fig. 1c). Finally, the less magnetized hybrids of the
target cells with the bead-tags are routed closer to the main
sedimentation direction into a slightly displaced, small detec-
tion chamber (labeled “capture” in Fig. 1c). Direction of rota-
tion is counter-clockwise (CCW), which means any corialis
effects will keep particles against the left-hand wall (Fig. 1c).
Due to the low speed of sedimentation of the particles in
stopped-flow mode, the impact of the Coriolis force was
found to be negligible, but the sense of spinning direction was
chosen as a precaution anyway.
Figure 1. a) Schematic of the polymeric “lab-on-a-disc” with microfluidic channels, visible in green, and magnets as silver cylinders. b)
Bright-field microscope image of two clusters of MCF7 cells tagged with paramagnetic beads (background beads are visible as dark
specks). c) Magnetic field simulation of one of the green chambers from (a), with trajectories for blood cells, magnetically tagged (cancer)
cells and excess magnetic beads. The directions of the centrifugal and magnetic fields are also indicated. Blood cells, excess beads, and
cancer cells are routed to the blood waste (“waste”), bead waste (“gutter”), and target cell capture chamber (“capture”), respectively.
Direction of rotation is CCW. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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In this way our design provides a low-stress, threefold
spatial separation of background blood cells, magnetically
tagged cancer cells and excess tagging beads. Compared with
standard, batch-mode immunomagnetic separation with a
simple magnet, our continuous, sedimentation-driven system
separates the latter two magnetic particles without the error-
prone size filtration. Furthermore, the novel, stopped-flow
mode inherently eliminates flow-field instabilities which tend
to compromise resolution. Also, magnetostatic, batch-mode
immunoseparation often leads to collective entrapment of
rare target cells in a cohort of background cells. This loss
mechanism is suppressed through the radially stretched distri-




The manufacture of the microfluidic discs was based on
the design from the author’s previously published work (31).
In brief, the discs were formed from polydimethylsiloxane
(PDMS) (Sylgard 184, Dow Corning; #101697, Farnell, UK)
by standard soft lithography methods (31) from a design
drawn with AutoCAD (Autodesk, Inc., CA). A 100-lm thick
dry-film photoresist (DuPont, NC) was hot-roll laminated
onto a 4” silicon wafer, lithographically structured by UV
exposure and developed according to the manufacturer’s
instructions. The dry film structures left on the wafer define
the PDMS casted channels. The millimetre-scale indentations
for magnet positioning (Fig. 3) were engineered with a three-
dimensional-printed polymer mould (uPrint, Stratasys Ltd.,
MN) and aligned via guide pins to create highly reproducible
discs with both, micro- and macrofeatures. After the PDMS
had been poured into the mould and hardened in the oven (1
hr at 70C), the discs were assembled and then placed for 1 h
into a vacuum chamber to allowing subsequent, degas-driven
priming (35) with buffer (phosphate buffered saline [PBS]
with 10% EDTA and 1% casein). The magnets (S-03–06-N,
Supermagnete, Germany) were then placed into the pre-
moulded voids on the PDMS disc.
The Centrifugal Spin-Stand
The microfluidic disc is then loaded with sample and
placed onto the custom designed centrifugal spin-stand (36)
featuring a servo motor (4490 series, Faulhaber, DE), a CCD
camera (Sensicam series, PCO, DE) connected to an optical
imaging system (Navitar, NY), and a strobe light all synchron-
ised via a PC (Dell). The system records one image per rota-
tion, giving the user a live feed of the cells and microparticles
as they sedimented through the microfluidic chambers. This
provided detailed trajectory information and real-time count-
ing of target cells, even during high-speed rotation.
Bead and Cell Binding
The basic separation mechanism here presented is depend-
ent on specific binding of the 4.5 mm magnetic microbeads to the
target cells of interest (Fig. 1c) (Dynabeads
VR
Epithelial Enrich,
Invitrogen Inc.). The Dynabeads were diluted 80-fold from stock
and incubated at a 1:1 volume ratio with MCF7 cells spiked. All
culture reagents were obtained from Sigma-Aldrich (MO) unless
otherwise stated. MCF7 cells (DSMZ, Braunschweig, Germany)
were cultured in 75 cm3 flasks in DMEM media, supplemented
with 10% uninactivated fetal bovine serum (FBS), 100 U/ml peni-
cillin and 100 mg/ml streptomycin. Cultures were maintained at
37C with 5% CO2. Cells were harvested by incubation in 5 ml
0.25% trypsin/0.1% EDTA at 37C for 5 min followed by neutral-
ization with 5 ml culture medium. Cells were centrifuged at 300g
for 4 min and resuspended in culture medium. Where indicated,
live cells were fluorescently labeled with NucBlueTM Live Cell
Stain (Life Technologies, CA) according to manufactures instruc-
tions. Whole blood, MCF7 cells and Dynabeads were incubated
in a capped 2 ml tube on a rotator for approximately 10 min at
Figure 2. a) In a flow based system, any particles entering a wide chamber will follow the expanding streamlines and fill the whole struc-
ture. The Comsol Multiphysics simulation indicates the velocity field in such a flow-based chamber. b) In a stopped-flow, centrifugal sedi-
mentation based system, particles entering a wide chamber will continue on their radial trajectory unless deflected by another force. c)
Image obtained of bulk blood cells traveling radially outward while a magnetically tagged cancer cell is additionally deflected by a laterally
placed magnet. The yellow line shows the path taken by the tagged cancer cell. (Video of separation can be found in Supporting Informa-
tion.) [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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room temperature. It was noted that substantial MCF7-cell-to-
bead binding was observed within less than 5 min.
EXPERIMENTAL RESULTS
Centrifugo-Magnetophoresis
Following incubation of the sample with magnetic beads
(cf. Materials and Methods section), a 3 ml aliquot was loaded
into each of the six chambers of the prepared microfluidic
disc, providing a total volume of 18 ll. This sample of whole
blood, tagged MCF7 cells and excess beads was then sedimen-
ted through the system by rotating the disc at a rate of 17 Hz
(55 g at edge of disc). When viewed using a zoomed real-time
video stream of the microfluidic chambers, within 10 s the
first of the tagged MCF7 cells exit the focusing channel and
are then deflected by the magnetic field into the separation
chamber (Fig. 2c, also see video in Supporting Information).
Within 1 min the MCF7 target cells are routed to their desig-
nated capture area (Fig. 3). The remainder of the particles
(untargeted red and white blood cells, beads, and the remain-
ing tagged cells) continue to sediment down the chamber to
their respective capture areas (Fig. 1c); within 10 min the sep-
aration is completed. As shown in Figure 3, the centrifugo-
magnetic stopped-flow system very accurately and reproduci-
bly separates a very small number of target cancer cells from a
background of a whole blood (as low as 1 cell/ll). Further-
more, the system can also very efficiently segregate the
unbound background beads without error-prone steps such as
size filtration. This removal of the unbound beads is of critical
importance for the quantitation of the captured cells, as, oth-
erwise, their presence in the target chamber would influence
the level of packing measured.
Detection and Quantification
In order to engineer a low-cost and easy to use system, we
obviated the need for any complex procedure and costly fluo-
rescence imaging. Unlike many other published instrumenta-
tion (17,18) the specificity of detection in our system is not
based on the binding of a specific fluorescent antibody, but
rather on the specificity of the magnetic beads to the target
cells of interest. As these cells are isolated from the background
sample, and specifically directed to a dedicated detection locus,
our here presented detection technique is based simply on ana-
lyzing the extent of occupation of this locus using bright-field
imaging (Fig. 3a). The dark areas shown represent clusters of
target cells surrounded with magnetic beads which are tightly
packed by the centrifugal field. The darkness of the filling arises
from the bead tags, and this facilitates simple image processing
to quantify the extent of packing.
The surface area of the pack was found to be directly pro-
portional to the (predefined) concentration of tagged cells in
our spiked sample (Fig. 4). In order to quantify the exact
number present for calibration purposes we fluorescently
labeled the MCF7 cells with NucBlue dye beforehand (Fig.
3b). Note that for the later analysis and quantification, only
the bright-field images were used.
We analyzed the bright-field images of the target cell cap-
ture chambers of all structures on the disc. Due to the high
contrast of the cell/bead pack with respect to the background in
Figure 3. a) Bright-field image showing the magnetically tagged MCF7 cells in the capture chamber. This method was used for counting
the dark pixels (tagged MCF7s) with the freeware ImageJ software (Fig. 4). b) Fluorescent merge image displaying the same magnetically
tagged and NucBlue stained MCF7 cells in the capture chamber. This method was used to enumerate the amount of MCF7 cells present in
the entire system, including any cells which did not reach the capture chamber (not shown). Chamber width: 150 lm. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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the capture chambers, a straight-forward method as part of the
freeware image analysis software ImageJ (ImageJ, U.S. National
Institutes of Health, MD) could be employed to enumerate the
number of dark pixels in a predefined region of interest, and
thus measure the extent of packing within each sample. A more
indepth explanation of the image analysis is given in the Sup-
porting Information. In brief, the background signal defined a
threshold value and the image was converted to an 8-bit binary
picture. The histogram could then be adjusted to provide the
maximum contrast between the dark bead/cell clusters and the
bright background. This gave a clear count of only the black
pixels and widely suppressed noise from untagged blood cells
or other stray particles. A set of six discs, with each running
five identical samples, was analyzed using this method.
The total amount of MCF7 cells present in each of the
whole blood tests, and the corresponding area calculated by
the dark packing fraction method are shown in Figure 4. The
correlation between packing area and known input is demon-
strated by the standard curve of the graph. These estimated
values correlated directly with the actual values shown in Fig-
ure 5, while the analysis strategy successfully identified the
“healthy” sample (i.e. zero cancer cells) and also correctly
assigned the values to the increasing concentrations of cancer-
cell spiked samples that were as low as a single MCF7 cell per
ll of whole blood sample. The capture efficiency, i.e. the ratio
between the number of cancer cells retrieved after centrifugo-
magnetic purification versus the total number of cancer cells
introduced into the chip, is 80% on average, peaking at 88%
for the highest concentration.
DISCUSSION
We have presented the centrifugo-magnetophoretic puri-
fication and bright-field based quantification of rare cells
from whole blood. A test on a total 18 ml of sample rapidly
completes within 10 min on our lab-on-a-disc system; the first
target cells are even detected in less than 1 min, which might
be beneficial if the sheer presence of the diagnostic target cell
was relevant (e.g. in the case of circulating tumour cells). The
mean recovery ratio of the target cells was 80%, peaking at
88% toward higher concentrations. The target cell population
can be quantified by a low-cost, bight-field opto-mechanical
setup incorporating a spindle motor and a CCD-based read-
out akin to an optical disc drive like a CD or DVD player. We
also note that this system could detect cells at a much lower
concentration than here presented if the sample was purified
and concentrated before the centrifugo-magnetophoretic pro-
cedure, e.g. by band extraction of the buffy coat or lysis of the
erythrocytes. It is also worth noting that while EpCAM was
used in these particular experiments, any target (or combina-
tion of targets) can be used through adoption of widely recog-
nized bead technologies and bead-binding chemistries. Our
system may thus be readily advanced to a compact, rapid,
accurate, and fully automated sample-to-answer (rare) cell
counter for point-of-care diagnostics.
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